Monoclonal antibodies: potential role in radiation therapy and oncology.
Specificity, which is a hallmark of the immune system, will be used in radiation oncology in both diagnosis and therapy through the application of radiolabelled monoclonal and polyclonal antibodies. Antigenic specificities, antibody preparations, and the tumor as a target for radiolabelled antibody is reviewed. Several clinical situations, i.e. single tumor cell suspensions, intraperitoneal single cells and masses, and solid tumors are reviewed in regard to both immune antibody targeting and specific differences between tumors in these regions. The concentration of tumor associated antigens is introductory to radiolabelled antibodies in diagnosis. In the radiation therapy of solid tumors, data regarding tumor dose, tumor effective half-life, varied antibody preparations, and the use of radiolabelled antibody as a method of tumor implantation is discussed using antiferritin 131I-IgG as a model as a model in hepatoma. The theoretical applications of monoclonal antibody integrated in cancer therapy are then presented as a new goal for future development.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007457:Iodine Radioisotopes; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D013601:T-Lymphocytes / Q000276:immunology; D013679:Technology, Radiologic
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007074:Immunoglobulin G; D007457:Iodine Radioisotopes